AU2019282327B2 - Dosing and effect of C5A antagonist with ANCA-associated vasculitis - Google Patents

Dosing and effect of C5A antagonist with ANCA-associated vasculitis Download PDF

Info

Publication number
AU2019282327B2
AU2019282327B2 AU2019282327A AU2019282327A AU2019282327B2 AU 2019282327 B2 AU2019282327 B2 AU 2019282327B2 AU 2019282327 A AU2019282327 A AU 2019282327A AU 2019282327 A AU2019282327 A AU 2019282327A AU 2019282327 B2 AU2019282327 B2 AU 2019282327B2
Authority
AU
Australia
Prior art keywords
treatment
avacopan
level
complement factor
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019282327A
Other languages
English (en)
Other versions
AU2019282327A1 (en
Inventor
Petrus BEKKER
Jun Deng
Jan HILLSON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemocentryx Inc
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of AU2019282327A1 publication Critical patent/AU2019282327A1/en
Application granted granted Critical
Publication of AU2019282327B2 publication Critical patent/AU2019282327B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2019282327A 2018-06-07 2019-06-06 Dosing and effect of C5A antagonist with ANCA-associated vasculitis Active AU2019282327B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862682013P 2018-06-07 2018-06-07
US62/682,013 2018-06-07
PCT/US2019/035758 WO2019236820A1 (en) 2018-06-07 2019-06-06 Dosing and effect of c5a antagonist with anca-associated vasculitis

Publications (2)

Publication Number Publication Date
AU2019282327A1 AU2019282327A1 (en) 2021-01-07
AU2019282327B2 true AU2019282327B2 (en) 2025-04-24

Family

ID=68764799

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019282327A Active AU2019282327B2 (en) 2018-06-07 2019-06-06 Dosing and effect of C5A antagonist with ANCA-associated vasculitis

Country Status (15)

Country Link
US (2) US11191756B2 (https=)
EP (1) EP3801519A4 (https=)
JP (2) JP2021527062A (https=)
KR (2) KR20260027358A (https=)
CN (1) CN112423752A (https=)
AU (1) AU2019282327B2 (https=)
BR (1) BR112020024842A2 (https=)
CA (1) CA3102403A1 (https=)
CL (1) CL2020003171A1 (https=)
IL (1) IL279188B2 (https=)
MA (1) MA52808A (https=)
MX (1) MX2020013166A (https=)
SG (1) SG11202011961YA (https=)
WO (1) WO2019236820A1 (https=)
ZA (1) ZA202007615B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11191756B2 (en) 2018-06-07 2021-12-07 Chemocentryx, Inc. Dosing and effect of C5a antagonist with ANCA-associated vasculitis
WO2020112961A1 (en) 2018-11-30 2020-06-04 Chemocentryx, Inc. Capsule formulations
CN114867473A (zh) * 2019-11-08 2022-08-05 凯莫森特里克斯股份有限公司 补体成分c5a受体的盐形式
US11603356B2 (en) 2019-11-08 2023-03-14 Chemocentryx, Inc. Amorphous form of a complement component C5a receptor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019089534A1 (en) * 2017-10-31 2019-05-09 Chemocentryx, Inc. C5aR INHIBITOR REDUCTION OF URINARY sCD163

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1739078A1 (de) * 2005-05-30 2007-01-03 Jerini AG C5a-Rezeptor-Antagonisten
US20080188528A1 (en) 2006-12-22 2008-08-07 Biediger Ronald J Modulators of C3a receptor and methods of use thereof
RU2010138612A (ru) * 2008-02-20 2012-03-27 Джи2 ИНФЛЕММЕЙШН ПТИ ЛТД (AU) ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА ПРОТИВ C5аR
RS54998B1 (sr) * 2008-12-22 2016-11-30 Chemocentryx Inc Antagonisti c5ar
US20110275639A1 (en) 2008-12-22 2011-11-10 Chemocentryx, Inc. C5aR ANTAGONISTS
RS56332B1 (sr) 2010-06-24 2017-12-29 Chemocentryx Inc Antagonisti c5ar
DK3200791T3 (da) 2014-09-29 2020-05-25 Chemocentryx Inc Fremgangsmåder og mellemprodukter i fremstilling af C5AR- antagonister
WO2016166357A2 (en) 2015-04-17 2016-10-20 The Provost, Fellows, Foundation Scholars, & The Other Members Of Board, Of The College Of The Holy & Undiv. Trinity Of Queen Elizabeth, Near Dublin Method and assay for diagnosing rapidly progressive glomerulonephritis in a subject
EP3439658B1 (en) 2016-04-04 2021-11-24 ChemoCentryx, Inc. Soluble c5ar antagonists
US11191756B2 (en) 2018-06-07 2021-12-07 Chemocentryx, Inc. Dosing and effect of C5a antagonist with ANCA-associated vasculitis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019089534A1 (en) * 2017-10-31 2019-05-09 Chemocentryx, Inc. C5aR INHIBITOR REDUCTION OF URINARY sCD163

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JAYNE, DRW et al.: "Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis", Journal of the American Society of Nephrology, vol. 28, no. 9, 2017, pages 2756-2767, DOI: 10.1681/ASN.2016111179 *
SHI LEI ED - GASPARYAN ARMEN YURI: "Anti-neutrophil cytoplasmic antibody-associated vasculitis: prevalence, treatment, and outcomes", RHEUMATOLOGY INTERNATIONAL, vol. 37, no. 11, 2017-09-27, pages 1779 - 1788 *

Also Published As

Publication number Publication date
ZA202007615B (en) 2024-05-30
CA3102403A1 (en) 2019-12-12
MX2020013166A (es) 2021-03-29
JP2021527062A (ja) 2021-10-11
EP3801519A1 (en) 2021-04-14
AU2019282327A1 (en) 2021-01-07
MA52808A (fr) 2021-04-14
CN112423752A (zh) 2021-02-26
US11191756B2 (en) 2021-12-07
CL2020003171A1 (es) 2021-06-04
KR20210018906A (ko) 2021-02-18
EP3801519A4 (en) 2022-03-30
SG11202011961YA (en) 2020-12-30
US12350263B2 (en) 2025-07-08
WO2019236820A1 (en) 2019-12-12
IL279188B2 (en) 2026-04-01
US20220296576A1 (en) 2022-09-22
IL279188A (en) 2021-01-31
BR112020024842A2 (pt) 2021-03-02
US20190374524A1 (en) 2019-12-12
KR20260027358A (ko) 2026-02-27
IL279188B1 (en) 2025-12-01
JP2024114706A (ja) 2024-08-23

Similar Documents

Publication Publication Date Title
US12350263B2 (en) Dosing and effect of C5a antagonist with ANCA-associated vasculitis
US11779576B2 (en) Method of treating C3 glomerulopathy
JP7116490B2 (ja) 眼の炎症性障害および疾患の組合せ処置
WO2019018350A1 (en) TOPICAL ADMINISTRATION OF THERAPEUTIC AGENTS COMPRISING CELL PENETRATION PEPTIDES, FOR USE IN THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND OTHER OCULAR DISEASES
CA2919081C (en) Pharmaceutical compositions for intraocular administration comprising an antibacterial agent and an antiinflammatory agent
KR20180024010A (ko) 동결건조된 약제학적 조성물
US20230414550A1 (en) Combination of kynurenine and antigen presenting cells (apc) as therapeutics and methods for their use in immune modulation
US20220257580A1 (en) Treatment of c3 glomerulopathy using a c5a inhibitor
RU2835509C2 (ru) Дозирование и эффект c5a антагониста при anca-ассоциированном васкулите
EP3085371A1 (en) Parthenolide and its derivatives for use in the treatment of axonal damage
CN107106566A (zh) 晶状体硬化抑制剂
WO2008109521A2 (en) Method of treatment using atranorin
JP2016503043A (ja) 乾癬を処置するためのピドチモドの使用
KR102202819B1 (ko) 자몽 정유의 용도
WO2022036455A1 (en) Dual analgesic/anti-inflammatory compositions comprising cb2 receptor agonists, combinations, and methods of use thereof
EP4260844B1 (en) Ophthalmological compositions comprising poloxamer
HK40068309A (en) Treatment of arthritis
NZ624920A (en) Pharmaceutical compositions and methods of use of 4-pregenen-11ß-17-21-triol-3,20-dione derivatives

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)